Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
EDINBURGH, United Kingdom, May 30, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
-
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, May 14, 2019 (GLOBE NEWSWIRE) --...
-
EDINBURGH, United Kingdom, April 02, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients...
-
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, March 07, 2019 (GLOBE NEWSWIRE)...
-
EDINBURGH, United Kingdom, March 05, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients...
-
EDINBURGH, United Kingdom, Feb. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) today announced that two abstracts related to NUC-3373 were selected for presentation at the AACR Annual Meeting...
-
EDINBURGH, United Kingdom, Jan. 25, 2019 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company (the “Company”) focused on significantly improving treatment...
-
EDINBURGH, United Kingdom, Jan. 23, 2019 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients...
-
EDINBURGH, United Kingdom, Nov. 28, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients...
-
Favorable Data Presented at ESMO on NUC-1031 (Acelarin®) and NUC-3373 First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer Initiation of Phase III Study of Acelarin in...